Ruggenenti P, Schieppati A, Remuzzi G
Clinical Research Centre for Rare Diseases Aldo e Cele Daccò, Ospedali Riuniti di Bergamo, 24125, Bergamo, Italy.
Lancet. 2001 May 19;357(9268):1601-8. doi: 10.1016/S0140-6736(00)04728-0.
The prevalence of chronic renal disease is increasing worldwide. Most chronic nephropathies lack a specific treatment and progress relentlessly to end-stage renal disease. However, research in animals and people has helped our understanding of the mechanisms of this progression and has indicated possible preventive methods. The notion of renoprotection is developing into a combined approach to renal diseases, the main measures being pharmacological control of blood pressure and reduction of proteinuria. Lowering of blood lipids, smoking cessation, and tight glucose control for diabetes also form part of the multimodal protocol for management of renal patients. With available treatments, dialysis can be postponed for many patients with chronic nephropathies, but the real goal has to be less dialysis-in other words remission of disease and regression of structural damage to the kidney. Experimental and clinical data lend support to the notion that less dialysis (and maybe none for some patients) is at least possible.
慢性肾病在全球的患病率正在上升。大多数慢性肾病缺乏特异性治疗方法,会无情地进展至终末期肾病。然而,对动物和人类的研究有助于我们理解这种进展的机制,并指出了可能的预防方法。肾脏保护的概念正在发展成为一种针对肾脏疾病的综合方法,主要措施是药物控制血压和减少蛋白尿。降低血脂、戒烟以及严格控制糖尿病患者的血糖,也构成了肾病患者多模式治疗方案的一部分。有了现有的治疗方法,许多慢性肾病患者的透析可以推迟,但真正的目标必须是减少透析——换句话说,疾病缓解和肾脏结构损伤的消退。实验和临床数据支持了这样一种观点,即减少透析(甚至某些患者可能无需透析)至少是有可能的。